NEI Research News

Research suggests that age-related macular degeneration (AMD) decreases an essential fatty acid, preventing the formation of a class of protective molecules and reducing repair potential.

Researchers found that diabetes, age-related health conditions and other metabolic disorders can lead to a buildup of cholesterol in the retina, which could contribute to diabetic retinopathy.

Designed by researchers at NYU, Commute Booster routes public-transportation users through the “middle mile” — the part of a journey inside subway stations or other similar transit hubs.

A new study suggests that eye drops developed by Columbia University researchers could be a more effective–and comfortable–therapy for a common eye disease currently treated with injections into the eye.

Researchers from Johns Hopkins Medicine show that experimental drug may prevent or slow vision loss in people with diabetic retinopathy, a complication of diabetes.

In a University of California, Irvine-led study, researchers have discovered small-molecule drugs with potential clinical utility in the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).

Texas Congressman Pete Sessions visited the NIH March 27 to meet with NEI Director Michael F. Chiang, M.D., and to tour NEI’s Section on Ocular and Stem Cell Translational Research, led by Kapil Bharti, Ph.D.

A National Eye Institute-led team has identified a compound already approved by the U.S. Food and Drug Administration that keeps light-sensitive photoreceptors alive in three models of Leber congenital amaurosis type 10 (LCA 10).

Researchers at the University of Alabama at Birmingham discovered that night vision tests at a specific location in the retina will be suitable for assessing treatments and preventions for AMD.

Indiana University researchers have identified a new therapeutic target that could lead to more effective treatment of glaucoma.